Compare Eli Lilly And Co (LLY) vs 3M Company (MMM) Price & Performance

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

3M (MMM) trades at $159.96, down 1.33% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.40 versus $2.25 expected, and maintains a robust net income margin of 11.9%. Recent news highlights operational momentum, including raised guidance and progress on litigation management. Cash flow from operations improved to $2.31 billion in 2025, though net cash flow was negative $319 million due to financing activities.

The outlook is mixed; analyst consensus is a Buy with a $191 price target, implying 19% upside, but technical indicators suggest near-term pressure. Key risks include high debt levels, weak consumer segment demand, and cost pressures. Earnings growth and margin expansion remain critical for sustained stock appreciation amid competitive and macroeconomic challenges.